

















Peregrine to Report Third Quarter Fiscal Year 2011 Financial Results After Market Close on March 11, 2011
Published in Health and Fitness on Friday, March 4th 2011 at 5:05 GMT by Market Wire

TUSTIN, CA--(Marketwire - March 4, 2011) - Peregrine Pharmaceuticals, Inc. (
To listen to the live webcast or access the archived webcast available for 30 days, please visit: [ http://ir.peregrineinc.com/events.cfm ].
- To listen to the conference call, please call (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through March 25, 2011 by calling (800) 642-1687 or (706) 645-9291 and using passcode 42778420.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ([ www.avidbio.com ]), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at [ www.peregrineinc.com ].